Imipramine Remedica (Imipramine Hydrochloride)

Imipramine is a tricyclic antidepressant used primarily in the management of depressive disorders.

• Major depressive disorder: reduces depressive symptoms and improves functional outcomes.
• Depressive episodes in bipolar disorder: may be used as an adjunct to mood stabilizers to control depressive phases.
• Treatment‑resistant depression: considered when first‑line agents are ineffective, offering an alternative mechanism of action.

• Imipramine inhibits the neuronal reuptake of the monoamines norepinephrine and serotonin, leading to increased concentrations of these neurotransmitters in the synaptic cleft. It also exhibits antagonistic activity at muscarinic acetylcholine, histamine H1, and alpha‑1 adrenergic receptors, contributing to both its therapeutic effects and side‑effect profile.

Imipramine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dry mouth: reduced salivary secretion leading to thirst.
• Constipation: slowed gastrointestinal motility.
• Drowsiness or fatigue: central nervous system sedation.
• Blurred vision: due to anticholinergic activity.
• Orthostatic hypotension: dizziness upon standing.
• Weight gain: increased appetite and metabolic changes.

Serious or Rare Side Effects

• Cardiac arrhythmias: especially in patients with pre‑existing heart disease.
• Seizures: heightened risk in susceptible individuals.
• Severe hypotension: sudden drop in blood pressure.
• Suicidal thoughts: worsening depression in early treatment.
• Agranulocytosis: rare but potentially life‑threatening blood disorder.

Before initiating therapy, clinicians should consider several safety factors.

• Cardiovascular assessment: obtain baseline ECG and monitor for arrhythmias.
• CNS effects: caution in patients with a history of seizures.
• Drug interactions: review concomitant medications for serotonergic activity.
• Age considerations: use lower doses in elderly due to anticholinergic burden.
• Pregnancy and lactation: evaluate risk‑benefit before prescribing.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Imipramine interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use can precipitate serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: combined serotonergic effect may increase syndrome risk.
• Certain antiarrhythmics (e.g., quinidine): may exacerbate cardiac toxicity.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can raise imipramine plasma levels.

• Antihistamines or other anticholinergics: additive anticholinergic burden.
• Diuretics or antihypertensives: may potentiate orthostatic hypotension.